A Randomized Clinical Trial Comparing an Acceptance-based Behavior Therapy to Applied Relaxation for Generalized Anxiety Disorder
Overview
Affiliations
Objective: To examine whether an empirically and theoretically derived treatment combining mindfulness- and acceptance-based strategies with behavioral approaches would improve outcomes in generalized anxiety disorder (GAD) over an empirically supported treatment.
Method: This trial randomized 81 individuals (65.4% female, 80.2% identified as White, average age 32.92) diagnosed with GAD to receive 16 sessions of either an acceptance-based behavior therapy (ABBT) or applied relaxation (AR). Assessments at pretreatment, posttreatment, and 6-month follow-up included the following primary outcome measures: GAD clinician severity rating, Structured Interview Guide for the Hamilton Anxiety Rating Scale, Penn State Worry Questionnaire, Depression Anxiety Stress Scale, and the State-Trait Anxiety Inventory. Secondary outcomes included the Beck Depression Inventory-II, Quality of Life Inventory, and number of comorbid diagnoses.
Results: Mixed effect regression models showed significant, large effects for time for all primary outcome measures (ds = 1.27 to 1.61) but nonsignificant, small effects for condition and Condition × Time (ds = 0.002 to 0.20), indicating that clients in the 2 treatments improved comparably over treatment. For secondary outcomes, time was significant (ds = 0.74 to 1.38), but condition and Condition × Time effects were not (ds = 0.004 to 0.31). No significant differences emerged over follow-up (ds = 0.03 to 0.39), indicating maintenance of gains. Between 63.3 and 80.0% of clients in ABBT and 60.6 and 78.8% of clients in AR experienced clinically significant change across 5 calculations of change at posttreatment and follow-up.
Conclusion: ABBT is a viable alternative for treating GAD. (PsycINFO Database Record (c) 2013 APA, all rights reserved).
Gandarela L, de A Sampaio T, Marcal L, Burdmann E, Neto F, Bernik M Brain Behav Immun Health. 2024; 38:100779.
PMID: 38725444 PMC: 11081778. DOI: 10.1016/j.bbih.2024.100779.
Berg H, Akeman E, McDermott T, Cosgrove K, Kirlic N, Clausen A J Mood Anxiety Disord. 2024; 1.
PMID: 38384390 PMC: 10881118. DOI: 10.1016/j.xjmad.2023.100004.
Papola D, Miguel C, Mazzaglia M, Franco P, Tedeschi F, Romero S JAMA Psychiatry. 2023; 81(3):250-259.
PMID: 37851421 PMC: 10585589. DOI: 10.1001/jamapsychiatry.2023.3971.
Newman M, Basterfield C, Erickson T, Caulley E, Przeworski A, Llera S Expert Rev Neurother. 2022; 22(9):751-770.
PMID: 36107159 PMC: 9754763. DOI: 10.1080/14737175.2022.2125800.
Vera M, Oben A, Juarbe D, Hernandez N, Perez-Pedrogo C J Behav Cogn Ther. 2022; 31(2):91-103.
PMID: 35813157 PMC: 9269989. DOI: 10.1016/j.jbct.2020.11.007.